-
Je něco špatně v tomto záznamu ?
Non-coding transcriptome profiles in clear-cell renal cell carcinoma
T. Tesarova, O. Fiala, M. Hora, R. Vaclavikova
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
- MeSH
- karcinom z renálních buněk * genetika diagnóza MeSH
- lidé MeSH
- nádorové biomarkery * genetika MeSH
- nádory ledvin * genetika diagnóza MeSH
- nekódující RNA * genetika MeSH
- prognóza MeSH
- regulace genové exprese u nádorů MeSH
- stanovení celkové genové exprese MeSH
- transkriptom * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Clear-cell renal cell carcinoma (ccRCC) is a common urological malignancy with an increasing incidence. The development of molecular biomarkers that can predict the response to treatment and guide personalized therapy selection would substantially improve patient outcomes. Dysregulation of non-coding RNA (ncRNA) has been shown to have a role in the pathogenesis of ccRCC. Thus, an increasing number of studies are being carried out with a focus on the identification of ncRNA biomarkers in ccRCC tissue samples and the connection of these markers with patients' prognosis, pathological stage and grade (including metastatic potential), and therapy outcome. RNA sequencing analysis led to the identification of several ncRNA biomarkers that are dysregulated in ccRCC and might have a role in ccRCC development. These ncRNAs have the potential to be prognostic and predictive biomarkers for ccRCC, with prospective applications in personalized treatment selection. Research on ncRNA biomarkers in ccRCC is advancing, but clinical implementation remains preliminary owing to challenges in validation, standardization and reproducibility. Comprehensive studies and integration of ncRNAs into clinical trials are essential to accelerate the clinical use of these biomarkers.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009766
- 003
- CZ-PrNML
- 005
- 20250429135338.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41585-024-00926-3 $2 doi
- 035 __
- $a (PubMed)39242964
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Tesarova, Tereza $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic. tereza.tesarova@szu.cz $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. tereza.tesarova@szu.cz $1 https://orcid.org/0000000210357375
- 245 10
- $a Non-coding transcriptome profiles in clear-cell renal cell carcinoma / $c T. Tesarova, O. Fiala, M. Hora, R. Vaclavikova
- 520 9_
- $a Clear-cell renal cell carcinoma (ccRCC) is a common urological malignancy with an increasing incidence. The development of molecular biomarkers that can predict the response to treatment and guide personalized therapy selection would substantially improve patient outcomes. Dysregulation of non-coding RNA (ncRNA) has been shown to have a role in the pathogenesis of ccRCC. Thus, an increasing number of studies are being carried out with a focus on the identification of ncRNA biomarkers in ccRCC tissue samples and the connection of these markers with patients' prognosis, pathological stage and grade (including metastatic potential), and therapy outcome. RNA sequencing analysis led to the identification of several ncRNA biomarkers that are dysregulated in ccRCC and might have a role in ccRCC development. These ncRNAs have the potential to be prognostic and predictive biomarkers for ccRCC, with prospective applications in personalized treatment selection. Research on ncRNA biomarkers in ccRCC is advancing, but clinical implementation remains preliminary owing to challenges in validation, standardization and reproducibility. Comprehensive studies and integration of ncRNAs into clinical trials are essential to accelerate the clinical use of these biomarkers.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x genetika $x diagnóza $7 D002292
- 650 12
- $a nádory ledvin $x genetika $x diagnóza $7 D007680
- 650 12
- $a nekódující RNA $x genetika $7 D022661
- 650 12
- $a transkriptom $7 D059467
- 650 12
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a stanovení celkové genové exprese $7 D020869
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine in Pilsen and University Hospital, Charles University, Pilsen, Czech Republic $u Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Hora, Milan $u Department of Urology, Faculty of Medicine in Pilsen and University Hospital, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000250613687 $7 mzk2004258359
- 700 1_
- $a Vaclavikova, Radka $u Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic $u Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 773 0_
- $w MED00184385 $t Nature reviews. Urology $x 1759-4820 $g Roč. 22, č. 3 (2025), s. 151-174
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39242964 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135333 $b ABA008
- 999 __
- $a ok $b bmc $g 2311254 $s 1246847
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 22 $c 3 $d 151-174 $e 20240906 $i 1759-4820 $m Nature reviews. Urology $n Nat Rev Urol $x MED00184385
- LZP __
- $a Pubmed-20250415
